Objective:A study to evaluate the safety and immunogenicity of a single dose of MVA expressing HIV-1 clade C env/gag-pol and nef-tat fusion genes (ADMVA).
Prevention Option(s):HIV Vaccine
Arms and Assigned Interventions
DescriptionADMVA administered to volunteers who previously received three doses of a clade C DNA Vaccine ADVAX e/g + ADVAX p/n-t
Mode of DeliveryIntramuscular
Official Code: IAVI C003
Trial Sponsors: Aaron Diamond AIDS Research Center, University of Rochester Medical Center
Age range: ↔ any